Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate

Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.

DealWatch_1200x675

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

Ahead of the planned spin-off of its Bausch + Lomb division,Bausch Health Companies Inc. is seeking to expand its...

More from Deals

More from Business